1. Bobadilla NA, Gamba G. New insights into the
pathophysiology of cyclosporine nephrotoxicity: A role of
aldosterone. Am J Physiol Renal Physiol 2007;293(1):2- 9.
2. Hortelano S, Castilla M, Torres AM, Tejedor A, Bosca L.
Potentiation by nitric oxide of cyclosporin A and FK506-
induced apoptosis in renal proximal tubule cells. J Am Soc
Nephrol 2000;11:2315-23.
3. Yılmaz VT, Gürkan A, Süleymanlar İ, Dinçkan A, Koçak
H, Ersoy FF, Yakupoğlu G, Süleymanlar G. Maintenance
ımmunosuppressive therapy in renal transplantation:
General considerations and Akdeniz University experience.
Turkiye Klinikleri J Nephrol-Special Topics 2010;3:18-34.
4. Clive DM. Renal transplant-associated hyperuricemia and
gout. J Am Soc Nephrol 2000;11:974-9.
5. Alexander RT, Hoenderop JG, Bindels RJ. Molecular
determinants of magnesium homeostasis: Insights from
human disease. J Am Soc Nephrol 2008;19:1451-8.
6. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroidfree
immunosuppression with tacrolimus, mycophenolate
mofetil, and daclizumab induction in renal transplantation.
Transplantation 2005;79:807-14.
7. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena
FP; Sirolimus Renal Function Study Group: Improved
renal function in sirolimus-treated renal transplant patients
after early cyclosporine elimination. Transplantation
2002;74:1560-7.
8. Butani L. Investigation of pediatric renal transplant
recipients with heavy proteinuria after sirolimus rescue.
Transplantation 2004;78:1362-6.
9. Letavernier E, Pe’raldi MN, Pariente A, Morelon E,
Legendre C. Proteinuria following a switch from calcineurin
inhibitors to sirolimus. Transplantation 2005;80:1198-203.
10. Boratyńska M, Banasik M, Watorek E, Falkiewicz K,
Patrzałek D, Szyber P, Klinger M. Conversion to sirolimus
from cyclosporine may induce nephrotic proteinuria and
progressive deterioration of renal function in chronic allograft
nephropathy patients. Transplant Proc 2006;38:101-4.
11. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen
T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P,
Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy
M, Budde K, Goto N; DIRECT (Diabetes Incidence
after Renal Transplantation: Neoral C Monitoring Versus
Tacrolimus) Investigators. Results of an international
randomized trial comparing glucose metabolism disorders
and outcome with cyclosporine versus tacrolimus. American
Journal of Transplantation 2007;7:1506-14.12. Heisel O, Heisel R, Balshaw R, Keown P. New onset
diabetes mellitus in patients receiving calcineurin inhibitors:
A systematic review and meta-analysis. Am J Transplant
2004;4:583-95.
13. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC,
Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo
AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg
JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry
PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS,
Yamaguchi Y, et al. The Banff 97 working classification of
renal allograft pathology. Kidney International 1999;55:713-
23.
14. Bonato V, Barni R, Cataldo D, Collini A, Ruggieri G, De
Bartolomeis C, Dotta F, Carmellini M. Analysis of posttransplant
diabetes mellitus prevalence in a population of
kidney transplant recipients. Transplant Proc 2008;40:1888-
90.
15. Egbuna OI, Davis RB, Chudinski R, Pavlakis M, Rogers C,
Molakatalla P, Johnson SR, Karp S, Monaco AP, Tang H,
Hanto DW, Mandelbrot DA. Outcomes with conversion from
calcineurin inhibitors to sirolimus after renal transplantation
in the context of steroid withdrawal or steroid continuation.
Transplantation 2009; 88:684-92.
16. Chhabra D, Grafals M, Cabral B, Leventhal J, Parker M,
Gallon L. Late conversion of tacrolimus to sirolimus in a
prednisone-free immunosuppression regimen in renal
transplant patients. Clin Transplant 2010;24:199-206.
17. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin
inhibitor-sparing regimens in solid organ transplantation:
Focus on improving renal function and nephrotoxicity. Clin
Transplant 2008;22:1-15.
18. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M,
Oberbauer R, Brennan DC, Campistol JM, Racusen
L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J,
Neylan JF; Sirolimus CONVERT Trial Study Group.
Sirolimus CONVERT Trial Study Group. Conversion from
calcineurin inhibitors to sirolimus maintenance therapy in
renal allograft recipients: 24-month efficacy and safety results
from the CONVERT trial. Transplantation 2009;87:233-
42.
19. Tedesco-Silva H Jr, Vitko S, Pascual J, Eris J, Magee JC,
Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot
B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V,
Haas T; 2306 and 2307 Study Groups.;12-month safety and
efficacy of everolimus with reduced exposure cyclosporine in
de novo renal transplant recipients. Transpl Int 2007;20:27-
36.
20. Pascual J. Concentration-controlled everolimus (Certican):
Combination with reduced dose calcineurin inhibitors.
Transplantation 2005;79:76- 9.
21. Luan FL, Zhang H, Schaubel DE, Miles CD, Cibrik D,
Norman S, Ojo AO. Comparative risk of impaired glucose
metabolism associated with cyclosporine versus takrolimus
in the late posttransplant period. American Journal of
Transplantation 2008;8:1871-7.22. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R.
Meta-analysis of calcineurin-inhibitor-sparing regimens in
kidney transplantation. J Am Soc Nephrol 2011;22:2107-18.
23. Cardinal H, Froidure A, Dandavino R, Daloze P, Hébert
MJ, Colette S, Boucher A. Conversion from calcineurin
ınhibitors to sirolimus in kidney transplant recipients: A
Retrospective cohort study. Transplantation Proceedings
2009;41:3308-10.
24. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA.
Conversion from calcineurin inhibitors to sirolimus for
chronic renal allograft dysfunction: A systematic review of
the evidence. Transplantation 2006;82:1153-55.
25. Pascual J. Calcineurin inhibitors minimisation and antiproliferative
strategies. Nephrol Ther 2008;4:29-35.
26. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin
inhibitor withdrawal from sirolimus-based therapy in kidney
transplantation: A systematic review of randomized trials.
Am J Transplant 2005;5:1748-56.
27. Sert M, Celik A, Kural K, Ersan S, Ataca P, Atila K,
Cavdar C, Sifil A, Bora S, Gulay H, Camsari T. Results of
4-year analysis of conversion from calcineurin inhibitors to
mTOR inhibitors in renal transplant patients: Single-center
experience. Ren Fail 2011;33:789-94.
28. Basu A, Banerjee P, Contreras AG, Flynn E, Pal S. Calcineurin
inhibitor-induced and Ras-mediated overexpression of
VEGF in renal cancer cells involves mTOR through the
regulation of PRAS40. PLoS One 2011;6:e23919.
29. Alberú J. Clinical insights for cancer outcomes in renal
transplant patients. Transplant Proc 2010;42(9):36-40.
30. Feldmeyer L, Hofbauer GF, Böni T, French LE, Hafner
J. Mammalian target of rapamycin (mTOR) inhibitors
slow skin carcinogenesis, but impair wound healing. Br J
Dermatol 2012;166:422-4.
31. Stojanova J, Caillard S, Rousseau A, Marquet P. Posttransplant
lymphoproliferative disease (PTLD): Pharmacological,
virological and other determinants. Pharmacol Res
2011;63:1-7.
32. Epailly E, Albanell J, Andreassen A, Bara C, Campistol
JM, Delgado JF, Eisen H, Fiane AE, Mohacsi P, Schubert
S, Sebbag L, Turazza FM, Valantine H, Zuckermann A,
Potena L. Proliferation signal inhibitors and post-transplant
malignancies in heart transplantation: Practical clinical
management questions. Clin Transplant 2011;25:475-86.
33. Jiménez-Romero C, Manrique A, Marqués E, Calvo J, Sesma
AG, Cambra F, Abradelo M, Sterup RM, Olivares S, Justo
I, Colina F, Moreno E. Switching to sirolimus monotherapy
for de novo tumors after liver transplantation. A preliminary
experience. Hepatogastroenterology 2011;58:115-21.
Thank you for copying data from http://www.arastirmax.com
